Extended co-operation agreement to benefit Sartorius customers
Agreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.
The Siemens technology group and Sartorius Stedim Biotech (SSB) have signed a long-term co-operation agreement. This agreement provides that SSB will preferably use Siemens automation technologies, including industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC. These hardware and software components will be used in many products and solutions that SSB offers its customers for the development and manufacture of biopharmaceuticals, such as vaccines and monoclonal antibodies.
SSB has, for some time, already been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems. To standardize its own product portfolio even further, SSB will introduce a new, configurable automation system for its range of systems. Under the agreement, co-operation between the two companies will, therefore, be extended to further SSB products. These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems, such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT STR series, various filtration systems and the FlexAct system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.
“By introducing this new automation platform and further standardizing our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production,” explained Dr Oscar-Werner Reif, Chief Technology Officer at SSB. “We have found an ideal partner in Siemens as one of the leading companies in automation,” continued Dr Reif.
Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: “We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system lifecycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time-to-market.”
During this year’s ACHEMA trade show that will be taking place from June 11 to June 15, 2018, in Frankfurt, Germany, Siemens and Sartorius Stedim Biotech will be jointly presenting the FlexAct module, a first product based on the new automation platform. Visitors and all others interested are cordially invited to obtain first-hand information at the Siemens AG booth in Hall 11/C3. A presentation on this product will be held in German on June 12 at 1:30 pm. and in English on June 13 at 1:00 p.m. and on 14 June at 2:00 pm.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...